Mizuho lowered the firm’s price target on Waystar (WAY) to $42 from $50 and keeps an Outperform rating on the shares. The firm trimmed targets in the healthcare technology space citing competitive risk.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
- Waystar initiated with an Outperform at Leerink
- Waystar price target lowered to $44 from $53 at Goldman Sachs
- ‘AI Story Remains Intact’: UBS Selects AI Stocks to Buy in 2026 (Including One You’ve Likely Never Heard Of)
- Waystar falls after Anthropic introduces Claude for Healthcare
- Waystar weighed on by Anthropic expansion in healthcare, says Citi